Skip to content
Disclosery

Healthcare Value Capital, LLC

Follow

13F filer, CIK 1458461, Woodcliff Lake, NJ

Healthcare Value Capital, LLC reported $44,899,000 across 22 holdings for the quarter ended 2021-03-31, in a 13F-HR filed 2021-05-17. Its ten largest share positions make up 75.13% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0000919574-21-003613

Period
2021-03-31
Reported value
$44.9M
Holdings
22
Top 10 weight
75.13%
New
12
Sold out
7

Largest buys vs the previous quarter

SecurityShares changeApprox. value
PFEnew+100,000$3.62M
VYNE THERAP.new+400,000$2.74M
COLLnew+100,000$2.37M
IRWDnew+200,000$2.24M
AMRYT PHARMA LTD - SPNR ADRnew+155,555$2.17M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ABBVexited-35,000-$3.75M
VYNE THERAPEUTICS INCexited-2,000,000-$3.16M
MCKexited-10,000-$1.74M
JAZZexited-10,000-$1.65M
CAHexited-25,000-$1.34M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2021

Share positions as resolved from 13F-HR 0000919574-21-003613, largest first. % of portfolio is the value over $39,175,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
GILDGILEAD SCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: 70,000 shares; 2020Q1: 50,000 shares; 2020Q2: 50,000 shares; 2020Q3: 50,000 shares; 2020Q4: 50,000 shares; 2021Q1: 75,000 shares 75,000$4.85M12.37%+25,000Timeline
PFEPFIZER INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: not reported; 2020Q1: not reported; 2020Q2: not reported; 2020Q3: not reported; 2020Q4: not reported; 2021Q1: 100,000 shares 100,000$3.62M9.25%newTimeline
GLAXOSMITHKLINE PLC-ADRGLAXOSMITHKLINE PLC-ADRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: 100,000 shares; 2020Q1: 100,000 shares; 2020Q2: 100,000 shares; 2020Q3: 100,000 shares; 2020Q4: 100,000 shares; 2021Q1: 100,000 shares 100,000$3.57M9.11%0
CLOVIS ONCOLOGY INCCLOVIS ONCOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: 150,000 shares; 2020Q1: 250,000 shares; 2020Q2: 250,000 shares; 2020Q3: 250,000 shares; 2020Q4: 250,000 shares; 2021Q1: 450,000 shares 450,000$3.16M8.06%+200,000
VYNE THERAP.VYNE THERAP.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: not reported; 2020Q1: not reported; 2020Q2: not reported; 2020Q3: not reported; 2020Q4: not reported; 2021Q1: 400,000 shares 400,000$2.74M6.99%new
TYME TECHNOLOGIES INC COMTYME TECHNOLOGIES INC COMQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: 2,175,000 shares; 2020Q1: 2,175,000 shares; 2020Q2: 2,175,000 shares; 2020Q3: 2,175,000 shares; 2020Q4: 2,175,000 shares; 2021Q1: 1,500,000 shares 1,500,000$2.67M6.82%-675,000
COLLCOLLEGIUM PHARMACEUTICAL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: not reported; 2020Q1: not reported; 2020Q2: not reported; 2020Q3: not reported; 2020Q4: not reported; 2021Q1: 100,000 shares 100,000$2.37M6.05%newTimeline
IRWDIRONWOOD PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: not reported; 2020Q1: not reported; 2020Q2: not reported; 2020Q3: not reported; 2020Q4: not reported; 2021Q1: 200,000 shares 200,000$2.24M5.71%newTimeline
AMRYT PHARMA LTD - SPNR ADRAMRYT PHARMA LTD - SPNR ADRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: not reported; 2020Q1: not reported; 2020Q2: not reported; 2020Q3: not reported; 2020Q4: not reported; 2021Q1: 155,555 shares 155,555$2.17M5.53%new
ANTARES PHARMA INCANTARES PHARMA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: 300,000 shares; 2020Q1: 500,000 shares; 2020Q2: 500,000 shares; 2020Q3: 500,000 shares; 2020Q4: 500,000 shares; 2021Q1: 500,000 shares 500,000$2.06M5.25%0
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: not reported; 2020Q1: not reported; 2020Q2: not reported; 2020Q3: not reported; 2020Q4: not reported; 2021Q1: 100,000 shares 100,000$1.87M4.77%newTimeline
BMYBRISTOL-MYERS SQUIBB COQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: not reported; 2020Q1: not reported; 2020Q2: not reported; 2020Q3: not reported; 2020Q4: not reported; 2021Q1: 25,000 shares 25,000$1.58M4.03%newTimeline
MRKMERCK & CO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: not reported; 2020Q1: not reported; 2020Q2: not reported; 2020Q3: not reported; 2020Q4: not reported; 2021Q1: 20,000 shares 20,000$1.54M3.94%newTimeline
GREENLANE HLDGS INCGREENLANE HLDGS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: 175,000 shares; 2020Q1: 225,000 shares; 2020Q2: 250,000 shares; 2020Q3: 250,000 shares; 2020Q4: 250,000 shares; 2021Q1: 250,000 shares 250,000$1.33M3.38%0
AUPHAURINIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: not reported; 2020Q1: not reported; 2020Q2: not reported; 2020Q3: not reported; 2020Q4: not reported; 2021Q1: 100,000 shares 100,000$1.3M3.32%newTimeline
AZNASTRAZENECA PLC-SPONS ADRQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: not reported; 2020Q1: 75,000 shares; 2020Q2: not reported; 2020Q3: not reported; 2020Q4: not reported; 2021Q1: 25,000 shares 25,000$1.24M3.17%newTimeline
ADAMAS PHARMACEUTICALS INCADAMAS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: not reported; 2020Q1: not reported; 2020Q2: not reported; 2020Q3: 100,000 shares; 2020Q4: 100,000 shares; 2021Q1: 100,000 shares 100,000$480K1.23%0
GAMIDA CELL LTDGAMIDA CELL LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2019Q2: restricted; 2019Q3: restricted; 2019Q4: not reported; 2020Q1: not reported; 2020Q2: not reported; 2020Q3: not reported; 2020Q4: 50,000 shares; 2021Q1: 50,000 shares 50,000$405K1.03%0

Options

Puts and calls, as filed. The amount and value describe the underlying shares, not the option premium, so they stay out of % of portfolio (H5).

SecurityTypeAmountValueChange
ProShares UltraPro Short S&…ProShares UltraPro Short S&P 500 COMcall100,000$2.37Mnew
AMARIN CORP PLCAMARIN CORP PLC SPONS ADR NEWcall300,000$1.86M0
Proshares VIX Short-TermProshares VIX Short-Term Equitycall100,000$935K+50,000
IRWDIRONWOOD PHARMACEUTICALS INC COMMON STOCKcall50,000$559Knew

Sold out in Q1 2021

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ABBVABBVIE INC35,000$3.75Mshares
VYNE THERAPEUTICS INCVYNE THERAPEUTICS INC2,000,000$3.16Mshares
MCKMCKESSON CORP10,000$1.74Mshares
JAZZJAZZ PHARMACEUTICALS PLC10,000$1.65Mshares
CAHCARDINAL HEALTH INC25,000$1.34Mshares
MRNAMODERNA INC10,000$1.04Mput
NVAXNOVAVAX INC5,000$558Kput

How Q1 2021 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0000919574-21-003613 base2021-05-17acceptance time not in the bulk data set